Ruthigen Inc. Showcased in Video News Alert Summary on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2014) - Ruthigen Inc (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics, is showcased in a video by InvestmentPitch Media.

InvestmentPitch.com has produced a "video news alert" discussing Ruthigen Inc. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Ruthigen" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_l746xwjt/Ruthigen-Inc-NASDAQ-RTGN-Showcase-Company-for-July-15-2014

The company closed its IPO on March 26th, issuing 2,650,000 units at $7.25 per unit, raising net proceeds of $16.2 million.

The company's lead drug candidate, RUT58-60, is a broad spectrum anti-infective that Ruthigen is developing for the prevention and treatment of infection in surgical and trauma procedures.

Hoji Alimi, CEO stated, "We are poised to commence patient enrollment in the initial phase of our first human clinical trial using RUT58-60 in July 2014, and plan to complete our Phase 1/2 clinical trial in less than nine months. We believe that the completion of our recent initial public offering has provided Ruthigen with sufficient funding to complete our planned Phase 1/2 clinical trial and fund our operations for approximately 18 months."

RUT58-60 is the only broad-spectrum anti-infective drug candidate designed for prophylactic use during invasive surgical procedures, which has been shown in laboratory tests to eradicate both gram-positive and gram-negative bacteria, including antibiotic resistant bacteria in less than 30-seconds of contact time. It is important to note that the drug is used for prevention of infection associated with post abdominal surgery, a competitive clinical and economic advantage to traditional antibiotics which treat patients after the infection.

Additionally, pre-clinical trials have indicated that RUT58-60 does not promote resistance to bacteria or create superbugs, which are both common problems associated with antibiotics.

The company's clinical program targets an initial $700 million potential market in the prevention of infections associated with abdominal surgery, with the total market for prevention of infection in the U.S. surgical market estimated at $3 billion. To address this larger market, the company is actively developing formulations for prevention of infection in cardiovascular, spinal and orthopedic procedures.

The drug is designed to improve patient lives, re-define infection control in surgical procedures and deliver cost savings to hospitals.

The shares are trading at $6.00, and with 4.7 million shares outstanding, the company is capitalized at $28.2 million.

For more information, please visit the company's website www.ruthigen.com, call 707-525-9900 or email ir@ruthigen.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases, research reports and other market information. Please visit InvestmentPitch.com and browse the extensive library of investment videos.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan@investmentpitch.com